202 related articles for article (PubMed ID: 31989096)
1. Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study.
Zielinski GD; van Rein N; Teichert M; Klok FA; Rosendaal FR; van der Meer FJM; Huisman MV; Cannegieter SC; Lijfering WM
Res Pract Thromb Haemost; 2020 Jan; 4(1):141-153. PubMed ID: 31989096
[TBL] [Abstract][Full Text] [Related]
2. Persistence to direct oral anticoagulants for acute venous thromboembolism.
Dronkers CEA; Lijfering WM; Teichert M; van der Meer FJM; Klok FA; Cannegieter SC; Huisman MV
Thromb Res; 2018 Jul; 167():135-141. PubMed ID: 29843087
[TBL] [Abstract][Full Text] [Related]
3. Switching from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?
Toorop MMA; Chen Q; Kruip MJHA; van der Meer FJM; Nierman MC; Faber L; Goede L; Cannegieter SC; Lijfering WM
J Thromb Haemost; 2022 Feb; 20(2):339-352. PubMed ID: 34779140
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
[TBL] [Abstract][Full Text] [Related]
5. Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study.
Zielinski GD; van Rein N; Teichert M; Klok FA; Rosendaal FR; van der Meer FJM; Huisman MV; Cannegieter SC; Lijfering WM
Pharmacoepidemiol Drug Saf; 2021 Aug; 30(8):1027-1036. PubMed ID: 33822401
[TBL] [Abstract][Full Text] [Related]
6. The Number of Concomitant Drugs and the Safety of Direct Oral Anticoagulants in Routine Care Patients with Atrial Fibrillation.
van den Dries CJ; van Doorn S; Souverein P; Pajouheshnia R; Moons KGM; Hoes AW; Geersing GJ; van den Ham HA
TH Open; 2020 Oct; 4(4):e417-e426. PubMed ID: 33376941
[No Abstract] [Full Text] [Related]
7. Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation.
Benzimra M; Bonnamour B; Duracinsky M; Lalanne C; Aubert JP; Chassany O; Aubin-Auger I; Mahé I
Patient Prefer Adherence; 2018; 12():79-87. PubMed ID: 29379275
[TBL] [Abstract][Full Text] [Related]
8. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
[TBL] [Abstract][Full Text] [Related]
9. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy.
Zolfaghari S; Harenberg J; Froelich L; Wehling M; Weiss C
Semin Thromb Hemost; 2014 Feb; 40(1):121-8. PubMed ID: 24381153
[TBL] [Abstract][Full Text] [Related]
10. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
[TBL] [Abstract][Full Text] [Related]
11. Pattern of oral anticoagulant prescribing for atrial fibrillation in general practice: an observational study in The Netherlands.
Kager CC; Horsselenberg M; Korevaar JC; Wagner C; Hek K
BJGP Open; 2023 Mar; 7(1):. PubMed ID: 36720562
[TBL] [Abstract][Full Text] [Related]
12. Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis.
Ha FJ; Barra S; Brown AJ; Begley DA; Grace AA; Agarwal S
Int J Cardiol; 2018 Jul; 262():51-56. PubMed ID: 29606512
[TBL] [Abstract][Full Text] [Related]
13. The relationship between stroke severity and prior direct oral anticoagulant therapy in patients with acute ischaemic stroke and non-valvular atrial fibrillation.
Sakamoto Y; Okubo S; Nito C; Suda S; Matsumoto N; Abe A; Aoki J; Shimoyama T; Takayama Y; Suzuki K; Mishina M; Kimura K
Eur J Neurol; 2017 Nov; 24(11):1399-1406. PubMed ID: 28799181
[TBL] [Abstract][Full Text] [Related]
14. Quality of life after switching from well-controlled vitamin K antagonist to direct oral anticoagulant: Little to GAInN.
van Miert JHA; Kooistra HAM; Veeger NJGM; Westerterp A; Piersma-Wichers M; Meijer K
Thromb Res; 2020 Jun; 190():69-75. PubMed ID: 32315869
[TBL] [Abstract][Full Text] [Related]
15. Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism.
Keita I; Aubin-Auger I; Lalanne C; Aubert JP; Chassany O; Duracinsky M; Mahé I
Patient Prefer Adherence; 2017; 11():1625-1634. PubMed ID: 29026288
[TBL] [Abstract][Full Text] [Related]
16. Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation: Analysis of the Hungarian Health Insurance Fund Database.
Papp T; Kiss Z; Rokszin G; Fábián I; Márk L; Bagoly Z; Becker D; Merkely B; Aradi D; Dézsi CA; Járai Z; Csanádi Z
Clin Ther; 2023 Apr; 45(4):333-346. PubMed ID: 37028991
[TBL] [Abstract][Full Text] [Related]
17. Direct oral anticoagulants are associated with lower risk of dementia in patients with atrial fibrillation.
Sagris D; Ntaios G; Buckley BJR; Harrison SL; Underhill P; Lane DA; Lip GYH
Eur J Intern Med; 2024 Mar; 121():114-120. PubMed ID: 37914656
[TBL] [Abstract][Full Text] [Related]
18. Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Ozaki AF; Choi AS; Le QT; Ko DT; Han JK; Park SS; Jackevicius CA
Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e005969. PubMed ID: 32148102
[TBL] [Abstract][Full Text] [Related]
19. Catheter ablation in adult congenital heart disease on uninterrupted oral anticoagulation: Is it safe? Data from a large single-center study.
Foerschner L; Kriesmair J; Telishevska M; Kottmaier M; Bourier F; Reents T; Lengauer S; Lennerz C; Krafft H; Maurer S; Popa M; Kolb C; Deisenhofer I; Hessling G
Heart Rhythm; 2022 Apr; 19(4):648-655. PubMed ID: 34958942
[TBL] [Abstract][Full Text] [Related]
20. Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral Anticoagulants.
Trevisan M; Hjemdahl P; Clase CM; de Jong Y; Evans M; Bellocco R; Fu EL; Carrero JJ
Am J Kidney Dis; 2023 Mar; 81(3):307-317.e1. PubMed ID: 36208798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
